Trial Profile
A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Hepatitis B vaccine (Primary) ; ADVAX; Hepatitis B vaccine recombinant
- Indications Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- Acronyms HBV003
- Sponsors Vaxine
- 07 Apr 2024 Planned End Date changed from 1 Dec 2025 to 31 Dec 2026.
- 07 Apr 2024 Planned primary completion date changed from 1 Dec 2025 to 31 Dec 2025.
- 07 Apr 2024 Planned initiation date changed from 1 Sep 2023 to 30 Sep 2024.